Engaging healthcare providers to implement HIV pre-exposure prophylaxis
نویسندگان
چکیده
منابع مشابه
Healthcare providers' knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection.
OBJECTIVES Pre-exposure prophylaxis (PrEP) has proven biological efficacy in reducing the risk of sexual acquisition of HIV. Healthcare providers' (HCPs) knowledge of and attitudes to PrEP will be key to successful implementation. In England, PrEP is only available to men who have sex with men (MSM) through the open-label randomized PROUD pilot study of immediate or deferred use. METHODS In S...
متن کاملPre-Exposure Prophylaxis for HIV Prevention.
c ase vignet tes The first patient, a 46-year-old sexually active man who has sex with men, presents for routine primary care. He lives in New York City and reports that he is in a long-term, stable, open relationship with a male partner and that he has had multiple recent sexual encounters with acquaintances. A recent HIV test was negative. He has seasonal allergies, for which he occasionally ...
متن کاملHIV pre-exposure prophylaxis for women
Women and girls comprise nearly half of HIV-infected individuals globally and 20% of new infections in the United States, indicating an urgent need to optimise HIV prevention options in this population. HIV pre-exposure prophylaxis (PrEP) - where antiretrovirals are administered to HIV-non-infected individuals at risk of HIV acquisition - is a promising, female-controlled HIV prevention strateg...
متن کاملKnowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers
Providers are central to effective implementation of HIV pre-exposure prophylaxis (PrEP). Primary care providers (PCP) and infectious disease physicians (ID) in the US Air Force (USAF) participated in a cross-sectional survey regarding knowledge, attitudes, and beliefs toward HIV PrEP. Characteristics associated with PrEP knowledge were assessed in univariate and multivariate analyses.Among 403...
متن کاملPre-exposure prophylaxis to intensify the fight against HIV.
www.thelancet.com/infection Vol 14 June 2014 443 recommendations. Because this was a phase 2 trial that was not powered for comparison of regimens, a phase 3 trial is needed to compare the two doses of raltegravir in patients co-infected with HIV and tuberculosis. In the interim, despite fi ndings from the pharmacokinetic study in healthy volunteers showing a reduction in raltegravir trough con...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in HIV and AIDS
سال: 2012
ISSN: 1746-630X
DOI: 10.1097/coh.0b013e3283590446